The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Lecigon 20 mg/ml + 5 mg/ml + 20 mg/ml intestinal gel

Lobsor Pharmaceuticals ABPA23144/001/001

Main Information

Trade NameLecigon 20 mg/ml + 5 mg/ml + 20 mg/ml intestinal gel
Active SubstancesLevodopa
Carbidopa monohydrate
Dosage FormIntestinal gel
Licence HolderLobsor Pharmaceuticals AB
Licence NumberPA23144/001/001

Group Information

ATC CodeN04BA03 levodopa, decarboxylase inhibitor and COMT inhibitor


License statusAuthorised
Licence Issued26/11/2021
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back